Literature DB >> 17804663

Highly sensitive and broadly reactive quantitative reverse transcription-PCR assay for high-throughput detection of Rift Valley fever virus.

Brian H Bird1, Darcy A Bawiec, Thomas G Ksiazek, Trevor R Shoemaker, Stuart T Nichol.   

Abstract

Rift Valley fever (RVF) virus is a mosquito-borne virus associated with large-scale epizootics/epidemics throughout Africa and the Arabian peninsula. Virus infection can result in economically disastrous "abortion storms" and high newborn mortality in livestock. Human infections result in a flu-like illness, with 1 to 2% of patients developing severe complications, including encephalitis or hemorrhagic fever with high fatality rates. There is a critical need for a highly sensitive and specific molecular diagnostic assay capable of detecting the natural genetic spectrum of RVF viruses. We report here the establishment of a pan-RVF virus quantitative real-time reverse transcription-PCR assay with high analytical sensitivity (approximately 5 RNA copies of in vitro-transcribed RNA/reaction or approximately 0.1 PFU of infectious virus/reaction) and efficiency (standard curve slope = -3.66). Based on the alignments of the complete genome sequences of 40 ecologically and biologically diverse virus isolates collected over 56 years (1944 to 2000), the primer and probe annealing sites targeted in this assay are known to be located in highly conserved genomic regions. The performance of this assay relative to serologic assays is illustrated by testing of known RVF case materials obtained during the Saudi Arabia outbreak in 2000. Furthermore, analysis of acute-phase blood samples collected from human patients (25 nonfatal, 8 fatal) during that outbreak revealed that patient viremia at time of presentation at hospital may be a useful prognostic tool in determining patient outcome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17804663      PMCID: PMC2168471          DOI: 10.1128/JCM.00936-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Climate and satellite indicators to forecast Rift Valley fever epidemics in Kenya.

Authors:  K J Linthicum; A Anyamba; C J Tucker; P W Kelley; M F Myers; C J Peters
Journal:  Science       Date:  1999-07-16       Impact factor: 47.728

2.  Quantitative real-time PCR detection of Rift Valley fever virus and its application to evaluation of antiviral compounds.

Authors:  S Garcia; J M Crance; A Billecocq; A Peinnequin; A Jouan; M Bouloy; D Garin
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

3.  Update: outbreak of Rift Valley Fever--Saudi Arabia, August-November 2000.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2000-11-03       Impact factor: 17.586

4.  The pathogenesis of Rift Valley fever in lambs.

Authors:  B C EASTERDAY; M H McGAVRAN; J R ROONEY; L C MURPHY
Journal:  Am J Vet Res       Date:  1962-05       Impact factor: 1.156

5.  Rift Valley fever in humans in South Africa.

Authors:  B M McIntosh; D Russell; I dos Santos; J H Gear
Journal:  S Afr Med J       Date:  1980-11-15

6.  High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings.

Authors:  Jonathan S Towner; Tara K Sealy; Thomas G Ksiazek; Stuart T Nichol
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

7.  Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR.

Authors:  Christian Drosten; Stephan Göttig; Stefan Schilling; Marcel Asper; Marcus Panning; Herbert Schmitz; Stephan Günther
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

8.  Rift Valley fever epizootic in the central highlands of Madagascar.

Authors:  J Morvan; P E Rollin; S Laventure; I Rakotoarivony; J Roux
Journal:  Res Virol       Date:  1992 Nov-Dec

9.  Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics.

Authors:  Tariq A Madani; Yagob Y Al-Mazrou; Mohammad H Al-Jeffri; Amin A Mishkhas; Abdullah M Al-Rabeah; Adel M Turkistani; Mohammad O Al-Sayed; Abdullah A Abodahish; Ali S Khan; Thomas G Ksiazek; Osama Shobokshi
Journal:  Clin Infect Dis       Date:  2003-09-23       Impact factor: 9.079

10.  Genetic analysis of viruses associated with emergence of Rift Valley fever in Saudi Arabia and Yemen, 2000-01.

Authors:  Trevor Shoemaker; Carla Boulianne; Martin J Vincent; Linda Pezzanite; Mohammed M Al-Qahtani; Yagub Al-Mazrou; Ali S Khan; Pierre E Rollin; Robert Swanepoel; Thomas G Ksiazek; Stuart T Nichol
Journal:  Emerg Infect Dis       Date:  2002-12       Impact factor: 6.883

View more
  69 in total

1.  Human Biomarkers of Outcome Following Rift Valley Fever Virus Infection.

Authors:  Anita K McElroy; Jessica R Harmon; Timothy Flietstra; Stuart T Nichol; Christina F Spiropoulou
Journal:  J Infect Dis       Date:  2018-10-20       Impact factor: 5.226

2.  Elevated antibodies against Rift Valley fever virus among humans with exposure to ruminants in Saudi Arabia.

Authors:  Ziad A Memish; Malak A Masri; Benjamin D Anderson; Gary L Heil; Hunter R Merrill; Salah U Khan; Ahmad Alsahly; Gregory C Gray
Journal:  Am J Trop Med Hyg       Date:  2015-02-02       Impact factor: 2.345

3.  Evaluation of the Efficacy, Potential for Vector Transmission, and Duration of Immunity of MP-12, an Attenuated Rift Valley Fever Virus Vaccine Candidate, in Sheep.

Authors:  Myrna M Miller; Kristine E Bennett; Barbara S Drolet; Robbin Lindsay; James O Mecham; Will K Reeves; Hana M Weingartl; William C Wilson
Journal:  Clin Vaccine Immunol       Date:  2015-06-03

4.  Virulence factor NSs of rift valley fever virus recruits the F-box protein FBXO3 to degrade subunit p62 of general transcription factor TFIIH.

Authors:  Markus Kainulainen; Matthias Habjan; Philipp Hubel; Laura Busch; Simone Lau; Jacques Colinge; Giulio Superti-Furga; Andreas Pichlmair; Friedemann Weber
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

5.  Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses.

Authors:  Kimberly A Dodd; Anita K McElroy; Megan E B Jones; Stuart T Nichol; Christina F Spiropoulou
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

6.  Molecular detection of Rift Valley fever virus in serum samples from selected areas of Tanzania.

Authors:  Augustino Alfred Chengula; Christopher Jacob Kasanga; Robinson Hammerthon Mdegela; Raphael Sallu; Mmeta Yongolo
Journal:  Trop Anim Health Prod       Date:  2014-01-24       Impact factor: 1.559

7.  NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase.

Authors:  Matthias Habjan; Andreas Pichlmair; Richard M Elliott; Anna K Overby; Timo Glatter; Matthias Gstaiger; Giulio Superti-Furga; Hermann Unger; Friedemann Weber
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

8.  Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention.

Authors:  Michel Pepin; Michele Bouloy; Brian H Bird; Alan Kemp; Janusz Paweska
Journal:  Vet Res       Date:  2010 Nov-Dec       Impact factor: 3.683

9.  Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus.

Authors:  Florian Zielecki; Michaela Weber; Markus Eickmann; Larissa Spiegelberg; Ali Moh Zaki; Mikhail Matrosovich; Stephan Becker; Friedemann Weber
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

10.  Multiple virus lineages sharing recent common ancestry were associated with a Large Rift Valley fever outbreak among livestock in Kenya during 2006-2007.

Authors:  Brian H Bird; Jane W K Githinji; Joseph M Macharia; Jacqueline L Kasiiti; Rees M Muriithi; Stephen G Gacheru; Joseph O Musaa; Jonathan S Towner; Serena A Reeder; Jennifer B Oliver; Thomas L Stevens; Bobbie R Erickson; Laura T Morgan; Marina L Khristova; Amy L Hartman; James A Comer; Pierre E Rollin; Thomas G Ksiazek; Stuart T Nichol
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.